Compare Medtronic PLC (MDT) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Verisign, Inc. — how do they compare? Medtronic PLC trades at $88.48 (market cap $112.24B), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Medtronic PLC is far larger — about 4.2× Verisign, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Verisign, Inc. for 123 Days on average.
| MDT | VRSN | |
|---|---|---|
Market Cap | $112.24B | $26.92B |
Volume | 105,663,236 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $105.35 | $310.00 |
52-Week Low | $73.75 | $211.49 |
Typical Hold Time | 63 Days | 123 Days |
Enterprise Value | $131.58B | $28.23B |
Dividend Yield | 3.28% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
VeriSign (VRSN) trades at $297.79, up 1.21% today, with a bullish technical signal and strong institutional interest. The company reported Q2 2026 EPS of $2.38, missing estimates, but maintains robust fundamentals with a 49.77% net income margin and $1.66B revenue in 2025. Recent news includes an upcoming Q3 earnings call and insider sales by the CEO, while an antitrust lawsuit poses a regulatory overhang.
The outlook remains positive with a consensus price target of $348, implying 17% upside, supported by steady cash flow growth and domain registration strength. Key risks include legal challenges and competitive pressures, but analyst sentiment is predominantly bullish with 60% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
